Document Detail

Rituximab therapy for childhood Evans syndrome.
MedLine Citation:
PMID:  18055994     Owner:  NLM     Status:  MEDLINE    
The safety and efficacy of rituximab have been retrospectively assessed in 17 children with Evans syndrome. Patients received 4 or 3 weekly doses of rituximab (375 mg/m(2) per dose) associated with prednisone, alone (14 patients) or associated with other immunosuppressive drugs. Complete or partial remission of at least one cytopenia was achieved in 13 out of the 17 patients (76%), and lasted in 11 of them with a mean follow-up of 2.4 years (range 0.5-7 years). Steroid therapy was stopped or tapered at 50-100% of the baseline dosage in all long-term responders. Moderate side effects and infection occurred only in 4 and 1 children respectively.
Brigitte Bader-Meunier; Nathalie Aladjidi; Françoise Bellmann; Fabrice Monpoux; Brigitte Nelken; Alain Robert; Corinne Armari-Alla; Capucine Picard; Françoise Ledeist; Martine Munzer; Karima Yacouben; Yves Bertrand; Antoine Pariente; Arnaud Chaussé; Yves Perel; Guy Leverger
Related Documents :
3278434 - Individualization of immediate posttransplant immunosuppression. the value of antilymph...
23726424 - Hazard perception of dutch farmers and veterinarians related to dairy young stock rearing.
6538004 - Myasthenia gravis: prolonged treatment with steroids.
22622694 - Dynamic co(2) inhalation: a novel treatment for csr-csa associated with chf.
19777604 - Balloon mitral valvotomy in patients with mitral stenosis and left atrial thrombus.
25349694 - Fasting during the month of ramadan among patients with chronic kidney disease: renal a...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Haematologica     Volume:  92     ISSN:  1592-8721     ISO Abbreviation:  Haematologica     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-12-06     Completed Date:  2008-04-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  1691-4     Citation Subset:  IM    
Assistance Publique-Hôpitaux de Paris, Service d'Hématologie-Oncologie Pédiatrique, Hôpital Robert Debré, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Hemolytic, Autoimmune / complications,  drug therapy*,  mortality
Antibodies, Monoclonal / administration & dosage*,  adverse effects
Child, Preschool
Disease-Free Survival
Follow-Up Studies
Immunologic Factors / administration & dosage*,  adverse effects
Infection / chemically induced,  mortality
Prednisolone / administration & dosage,  adverse effects
Purpura, Thrombocytopenic, Idiopathic / complications,  drug therapy*,  mortality
Remission Induction
Survival Rate
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunologic Factors; 0/rituximab; 50-24-8/Prednisolone
Comment In:
Haematologica. 2007 Dec;92(12):1589-96   [PMID:  18055980 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplas...
Next Document:  Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adul...